PBM formulary exclusions top 600 drugs as Caremark, Express Scripts and Optum Rx adjust 2026 lists amid pricing shifts.

The Federal Trade Commission said it has reached a settlement with Express Scripts, resolving an earlier lawsuit that alleged the pharmacy benefit manager artificially inflated insulin drug prices.

A landmark deal aims to end the pricing games that grossly inflate what you pay at the pharmacy.

The MarketWatch News Department was not involved in the creation of this content. Settlement resolves FTC lawsuit alleging that Express Scripts' conduct resulted in artificially inflated insulin drug ...

Federal regulators announced a settlement Wednesday with Express Scripts to change how the company handles prescription drug pricing. The agreement aims to lower out-of-pocket costs for patients who ...

The Federal Trade Commission reached a settlement with Cigna’s Express Scripts in a case over alleged inflation of insulin prices, according to a Feb. 4 agency news release. With the move, the FTC ...

Federal pharmacy benefit manager transparency reforms must contend with concentrated pharmaceutical markets that lack ...

On February 4, 2026, Express Scripts agreed to a settlement with the Federal Trade Commission (FTC) in the agency’s administrative case against the nation’s three largest pharmacy benefit managers ...

A group of former Wells Fargo & Co. employees are appealing to the US Court of Appeals for the Eighth Circuit after a federal judge in Minnesota dismissed their lawsuit challenging prescription drug ...

On February 4, 2026, the Federal Trade Commission (FTC) proposed to settle its enforcement action against leading pharmacy benefit manager (PBM) Express Scripts, going beyond the insulin products that ...